AtriCure, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04963C2098
USD
39.25
3.94 (11.16%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About AtriCure, Inc. stock-summary
stock-summary
AtriCure, Inc.
Pharmaceuticals & Biotechnology
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).
Company Coordinates stock-summary
Company Details
7555 Innovation Way , MASON OH : 45040-9695
stock-summary
Tel: 1 513 7554100
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 78 Schemes (56.13%)

Foreign Institutions

Held by 122 Foreign Institutions (17.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Scott Drake
Independent Chairman of the Board
Mr. Michael Carrel
President, Chief Executive Officer, Director
Mr. Mark Collar
Independent Director
Mr. Daniel Florin
Independent Director
Ms. Regina Groves
Independent Director
Ms. B. Kristine Johnson
Independent Director
Mr. Mark Lanning
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
136 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,789 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.11

stock-summary
Return on Equity

-4.17%

stock-summary
Price to Book

3.85